Sanofi India Ltd vs Zenlabs Ethica Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Sanofi India Ltd is ₹ 3402 as of 05 May 15:30 . The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 .The P/E Ratio of Zenlabs Ethica Ltd is 0 as of December 2023 . The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 .The Market Cap of Zenlabs Ethica Ltd is ₹ 0 crore as of December 2023 . The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 .The Revenue of Zenlabs Ethica Ltd is ₹ 0 crore as of Jun '24 . The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 .The EBITDA of Zenlabs Ethica Ltd is ₹ 0 crore as of Jun '24 . The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 .The Net Profit of Zenlabs Ethica Ltd is ₹ 0 crore as of Jun '24 . The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% The dividend payout of Zenlabs Ethica Ltd changed from 33.21 % to 0 % over 3 quarters. This represents a CAGR of -100.00% .

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

About Zenlabs Ethica Ltd

Zenlabs Ethica Limited (Formerly known Neelkanth Technologies Limited) was incorporated in 1993.
The Company is one of the top 10 pharmaceutical contract marketing and trading companies in India that markets and distribute a wide range of branded drugs including Gastrointestinal disorders, Anti-Diabetics, Anti-Hypertensive Drugs, Anti-Infective, Soaps & Anti-Bacterial Drugs, Nutraceuticals, etc., It boasts of a comprehensive global network.
It deals into marketing and distribution of pharmaceutical products and has grown to be of India's top pharmaceutical companies in 2019. The Company has been launched in collaboration with Zenlabs Pharmaceutical Inc, Canada.
The strength lies in quality, affordable and branded drugs in enhancing the quality of life of people.
Apart from this, it offers more than 600 products across therapeutic segments, making it a leader among pharmaceutical companies in India.

FAQs for the comparison of Sanofi India Ltd and Zenlabs Ethica Ltd

Which company has a larger market capitalization, Sanofi India Ltd or Zenlabs Ethica Ltd?

Market cap of Sanofi India Ltd is 8,111 Cr while Market cap of Zenlabs Ethica Ltd is 15 Cr

What are the key factors driving the stock performance of Sanofi India Ltd and Zenlabs Ethica Ltd?

The stock performance of Sanofi India Ltd and Zenlabs Ethica Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Sanofi India Ltd and Zenlabs Ethica Ltd?

As of May 5, 2026, the Sanofi India Ltd stock price is INR ₹3522.25. On the other hand, Zenlabs Ethica Ltd stock price is INR ₹23.42.

How do dividend payouts of Sanofi India Ltd and Zenlabs Ethica Ltd compare?

To compare the dividend payouts of Sanofi India Ltd and Zenlabs Ethica Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.